Login
Products
Login
Home
Alerts
Search
Watchlist
Products

Procter & Gamble Health Ltd

PGHL
NSE
5,135.00
0.43%
Last Updated:
29 Apr '26, 4:00 PM
Company Overview
Alert
Watchlist
Note

Procter & Gamble Health Ltd

PGHL
NSE
5,135.00
0.43%
29 Apr '26, 4:00 PM
Company Overview
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
8,524Cr
Close
Close Price
5,135.00
Industry
Industry
Pharma - MNC bulk Drugs
PE
Price To Earnings
29.04
PS
Price To Sales
6.32
Revenue
Revenue
1,349Cr
Rev Gr TTM
Revenue Growth TTM
16.30%
PAT Gr TTM
PAT Growth TTM
24.06%
Peer Comparison
How does PGHL stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
PGHL
VS

Quarterly Results

Upcoming Results on
26 May 2026
Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
321301305310252284313310311339325374
Growth YoY
Revenue Growth YoY%
19.81.82.50.0-21.3-5.72.8-0.123.219.33.720.7
Expenses
ExpensesCr
241256216208185236199186230248205263
Operating Profit
Operating ProfitCr
80458910267481141238190120110
OPM
OPM%
24.815.129.132.826.717.036.439.926.026.737.029.6
Other Income
Other IncomeCr
55652-18343454
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
676777665566
PBT
PBTCr
79448810063231111227989119109
Tax
TaxCr
19142228166293117233031
PAT
PATCr
593066724717829161668978
Growth YoY
PAT Growth YoY%
15.7-27.63.0-6.2-21.3-43.725.626.131.4294.47.5-14.6
NPM
NPM%
18.49.921.523.318.45.926.329.319.719.527.320.8
EPS
EPS
35.718.039.543.428.09.549.654.836.939.953.346.7

Profit & Loss

Standalone
Numbers
Percentage
Financial YearDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025TTM
Revenue
RevenueCr
8679409936988491,3561,0091,1141,2301,1519341,349
Growth
Revenue Growth%
8.78.35.7-29.721.6-25.610.510.3-6.444.4
Expenses
ExpensesCr
8098568776217011,040763847905845616947
Operating Profit
Operating ProfitCr
598311677148315246268325306318402
OPM
OPM%
6.88.911.611.017.423.324.424.026.426.634.129.8
Other Income
Other IncomeCr
202324413169181318-51016
Interest Expense
Interest ExpenseCr
000000101100
Depreciation
DepreciationCr
132325192129302728271723
PBT
PBTCr
678311599158355233253314273312395
Tax
TaxCr
23303638561015661857277102
PAT
PATCr
43547961102254177193229201234293
Growth
PAT Growth%
-22.723.947.7-22.966.7-30.48.919.2-12.425.2
NPM
NPM%
5.05.78.08.712.018.717.517.318.717.525.121.8
EPS
EPS
26.032.347.756.6505.3153.1106.5116.0138.2121.1141.2176.8

Balance Sheet

Standalone
Numbers
Percentage
Financial YearDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
171717171717171717171717
Reserves
ReservesCr
5385756477171,524890687600734522520603
Current Liabilities
Current LiabilitiesCr
135165186225193227239232304219215222
Non Current Liabilities
Non Current LiabilitiesCr
192729332742434046374252
Total Liabilities
Total LiabilitiesCr
7087848799911,7591,1769868881,101794794894
Current Assets
Current AssetsCr
4995726367521,534954727608796524526639
Non Current Assets
Non Current AssetsCr
210212243239225222259280305270268255
Total Assets
Total AssetsCr
7087848799911,7591,1769868881,101794794894

Cash Flow

Standalone
Financial YearDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
58310754-130235247170236228169
Investing Cash Flow
Investing Cash FlowCr
11-68-75-481,270165-32-26-22-710
Financing Cash Flow
Financing Cash FlowCr
-17-12-15-22-30-883-387-289-98-418-235
Net Cash Flow
Net Cash FlowCr
-1417-161,109-483-172-145116-197-56
Free Cash Flow
Free Cash FlowCr
-35387524-157212196132198207168
CFO To PAT
CFO To PAT%
11.4155.8135.387.9-128.292.6139.888.0102.8113.672.0
CFO To EBITDA
CFO To EBITDA%
8.4100.092.669.7-88.074.6100.563.372.774.653.0

Ratios

Standalone
Financial YearDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
1,3191,2931,6562,1395,1206,7519,2866,9518,7138,3828,536
Price To Earnings
Price To Earnings
32.025.320.922.86.139.952.536.138.041.727.3
Price To Sales
Price To Sales
1.51.41.73.16.05.09.26.27.17.39.1
Price To Book
Price To Book
2.42.22.52.93.37.513.211.311.615.615.9
EV To EBITDA
EV To EBITDA
19.613.211.924.226.219.435.924.825.526.626.2
Profitability Ratios
Profitability Ratios
GPM
GPM%
53.853.758.566.168.368.269.169.570.671.371.9
OPM
OPM%
6.88.911.611.017.423.324.424.026.426.634.1
NPM
NPM%
5.05.78.08.712.018.717.517.318.717.525.1
ROCE
ROCE%
12.014.117.413.510.339.132.941.041.350.057.3
ROE
ROE%
7.89.111.98.36.628.025.131.230.637.343.7
ROA
ROA%
6.16.89.06.25.821.617.921.720.825.329.5
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
### **Overview** Procter & Gamble Health Ltd (P&G Health), acquired by P&G in 2018, is one of India’s largest and most trusted players in the vitamins, minerals, and supplements (VMS) market. With a rich heritage spanning over five decades, the company markets well-established, science-backed health brands such as **Neurobion**, **Evion**, **Livogen**, **Seven Seas**, **Polybion**, and **Nasivion**. These brands address widespread health concerns including nerve health, iron deficiency, vitamin deficiencies, and respiratory wellness, serving millions of consumers across all life stages. P&G Health operates in a highly competitive, low-barrier VMS market where doctor (HCP) prescriptions influence approximately 70% of sales, with the remainder driven by chemist recommendations and consumer self-purchase—particularly strong for Neurobion Forte (50% self-purchase) and Evion (32%). --- ### **Market Leadership & Share Growth (FY2025)** - **Vitamin E Category Leader**: Evion continues to dominate the Indian Vitamin E segment, reinforced by repositioning efforts to highlight vitamin E’s role in **muscle health** and antioxidant protection. - **Record Category Share**: Achieved record growth in **Nerve Care, Vitamin E, and Nasal Decongestant** categories during FY2025, driven by brand strength, innovation, and superior execution. - **Expanded Pharmacy Reach**: Neurobion's retail footprint has grown 1.4x over five years, adding ~100,000 new pharmacy outlets, with ongoing expansion into rural and underserved regions. --- ### **Brand Performance & Strategy** #### **Neurobion – Flagship Nerve Health Brand** - **Trusted for Nerve Care**: Positioned as a trusted solution for symptoms like tingling, numbness, and weakness due to Vitamin B deficiency. - **Enhanced Product Portfolio**: - **Neurobion Alfa & Alfa D** (for diabetic neuropathy) show strong early growth, supported by scientific engagement with HCPs. - **Neurobion Forte** features improved packaging and labeling to enhance clarity and consumer decision-making. - **Awareness & Recognition**: Achieved highest-ever **unaided brand awareness**, driven by targeted campaigns on Peripheral Neuropathy in partnership with the **International Diabetes Federation**. - **Guinness World Record**: Recognized for Iron Deficiency Anemia awareness campaign in collaboration with FOGSI. #### **Evion – Market-Leading Vitamin E Brand** - **"Nourish Your Cells" → Broader Health Messaging**: Evolved from cell health to emphasize **muscle health and energy**, supported by direct-to-consumer (D2C) advertising. - **Five Vectors of Superiority**: Strategy built on product formulation, packaging, trade value, HCP engagement, and omnichannel retail execution. - **First D2C Push**: Successful TV and digital ad campaign launched in 2021 marked a key milestone in consumerization. #### **Livogen, Seven Seas, Polybion, Nasivion** - **Livogen**: The most prescribed iron supplement in India; brand messaging focused on "**Break Free from Iron Deficiency**". - **Seven Seas**: Focused on child nutrition via campaigns like **"My Little Genius"**, aligning with developmental needs. - **Polybion**: Expanded with **Polybion Active Syrup**—a sugar-free B-complex with lysine for diabetics and those with lifestyle disorders. - **Nasivion**: Delivers “**Fast Relief from Nasal Congestion**”; grew through media partnerships (cricket sponsorships, OTT integrations) and **‘OPEN UP’ expert education sessions**. --- ### **Strategic Initiatives & Go-to-Market Transformation** #### **Irresistible Superiority Strategy** P&G Health drives differentiation through an integrated five-vector framework: 1. **Product Superiority** (science-backed formulations) 2. **Packaging Innovation** (enhanced clarity and appeal) 3. **Brand Communication** (symptom-awareness focused) 4. **Retail Execution** (superior physical and digital presence) 5. **Consumer Value** (affordability with trust) All vectors are aligned to deliver **noticeable benefits**, compelling value, and effective consumer engagement. #### **Transformed Go-to-Market Model** - Built around a **strong super-distributor network** to improve reach, availability, and agility. - Enhances retail execution, HCP engagement, and access across **tier 2/3 towns and rural areas**. - Complements reach with **e-commerce expansion** and digital retail integration. #### **Scientific & Educational Leadership** - **P&G Health Academy**: A virtual platform connecting global experts for scientific exchange and HCP education. - Regular **scientific symposiums** and “phygital” detailing maintain engagement with healthcare professionals. - Campaigns like the **Peripheral Neuropathy initiative** (with IDF) and **'OPEN UP'** (Nasivion) reflect a commitment to public health education. --- ### **Consumer & Market Insights** - **High Deficiency, Low Awareness**: A significant portion of Indian adults suffer from **Vitamin B and iron deficiencies**, yet awareness of effective treatments remains limited. - **Substitution Challenge**: Generic substitutions at chemist level undermine treatment efficacy, reinforcing the need for brand trust and consumer education. - **Self-Purchase Trend**: Growing consumer agency, especially for Neurobion Forte and Evion, suggests success in direct consumer engagement. --- ### **Innovation & Operational Excellence** - **Continuous Product Improvement**: Focus on both innovation and iterative enhancements of existing products. - **Consumer Insights Integration**: Deep understanding of consumer needs informs formulation, packaging, and messaging. - **Productivity-Driven Model**: Embedded productivity initiatives support **margin expansion and balanced growth**. --- ### **Leadership & Organizational Strength** - **Lokesh Chandak (Appointed Apr 2023)**: Brings 15+ years of P&G leadership, with proven success in commercial finance, profitability improvement, and strategic turnarounds across India, Asia, MEA. - His expertise strengthens P&G Health’s focus on **financial stewardship, innovation, and operational efficiency**. --- ### **Digital & Hybrid Capabilities** - **Phygital Engagement**: Medical and sales teams utilize hybrid detailing (virtual + in-person) to maintain HCP and pharmacy relationships. - **Digital Campaigns**: Active use of **OTT, TV, digital display, and social media** enhances consumer engagement. - **E-commerce Leverage**: Expanding digital shelf presence to meet evolving consumer preferences.